Editas med stock.

Funding could be an issue. Editas Medicine ended the first quarter with $401.8 million in cash and equivalents, down from the $437.4 million it had at the end of 2022. In its quarterly update, the ...Mar 22, 2023 · Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 19.25% so far this month. During the month of March, Editas Medicine Inc’s stock price has reached a high of $9.18 and a low of $7.27. Over the last year, Editas Medicine Inc has hit prices as high as $21.60 and as low as $7.48. Year to date, Editas ... 11.34%. Get the latest Editas Medicine Inc (EDIT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Dec 1, 2023 · 12 Wall Street analysts have issued 1-year price objectives for Editas Medicine's stock. Their EDIT share price targets range from $7.00 to $30.00. On average, they expect the company's share price to reach $13.92 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price.

Discover historical prices for EDIT stock on Yahoo Finance. View daily, weekly or monthly format back to when Editas Medicine, Inc. stock was issued.

Dec 1, 2023 · 12 Wall Street analysts have issued 1-year price objectives for Editas Medicine's stock. Their EDIT share price targets range from $7.00 to $30.00. On average, they expect the company's share price to reach $13.92 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price.

CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA ...Hillevax Inc. 12.75. +0.65. +5.37%. Get Editas Medicine Inc (EDIT:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Nov 24, 2023 · The Editas Medicine, Inc stock price gained 0.86% on the last trading day (Friday, 24th Nov 2023), rising from $10.49 to $10.58. During the last trading day the stock fluctuated 3.71% from a day low at $10.50 to a day high of $10.89. The price has risen in 6 of the last 10 days and is up by 34.43% over the past 2 weeks. The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the fourth quarter and full ...Oct 7, 2023 · Editas Medicine. Market Cap. $860M. Today's Change. (-0.75%) -$0.08. Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may ...

View Georgia Giannoukos’ profile on LinkedIn, the world’s largest professional community. Georgia has 1 job listed on their profile. See the complete profile on LinkedIn and discover Georgia ...

Editas Medicine Stock Forecast 11-26-2023. Forecast target price for 11-26-2023: $ 10.97. Positive dynamics for Editas Medicine shares will prevail with possible volatility of 3.528%. Pessimistic target level: 10.80. Optimistic target level: 11.19.

Buying or selling a stock that's not traded in your local currency? Don't let the currency conversion trip you up. Convert Editas Medicine Inc stocks or shares ...Sep 30, 2020 · Current Price. $10.65. Price as of November 27, 2023, 4:00 p.m. ET. Both are working on gene-editing therapies, with plenty of potential upside. But which is the better stock right now? You can't ... Finance. Industry. MarketEditas Medicine. Market Cap. $860M. Today's Change. (-0.75%) -$0.08. Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may ...One of the top gene-editing stocks on the market is Editas Medicine (EDIT 0.86%). The biotech has been in business for less than five years and has only traded publicly for a little over two years.Feb 24, 2023 · In brief, Editas Medicine's lack of commercialized products, early-stage pipeline, pipeline setback, and termination of a strategic alliance with AbbVie have all hurt the stock's performance.

Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in ...Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors.Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions. See the latest Editas Medicine Inc stock price (EDIT:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to purchase up to an ...

On average, Wall Street analysts predict. that Editas Medicine's share price could reach $14.00 by Oct 24, 2024. The average Editas Medicine stock price prediction forecasts a potential upside of 31.95% from the current EDIT share price of $10.61.Editas Medicine has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock on the same terms and conditions. All of the shares in the offering ...In 2021, Vertex acquired the rights to 60% of the profits from sales of Crispr Therapeutics gene-editing therapy CTX001, now called exa-cel, for up to $1.1 billion, pending regulatory approval ...You can buy and sell Editas Medicine (EDIT) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. Other Robinhood Financial fees may apply, check rbnhd.co/fees for details. ... Over the last month the Editas Medicine, Inc. ( ) has been much stronger than before, rebounding by 72%.It's been a tough year for Editas Medicine (EDIT-0.26%) so far. As of the market close on Monday, the stock was down 42%. But shares of Editas were rebounding by 8.2% as of 11:25 a.m. EST on Tuesday.Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

8.300 USD. +8.50%. -5.57%. -4.61%. Nov. 03. Transcript : Editas Medicine, Inc., Q3 2023 Earnings Call, Nov 03, 2023. CI. Nov. 03. Editas Medicine, Inc. Reports Earnings …

Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Find the latest Unity Software Inc. (U) stock quote, history, news and other vital information to help you with your stock trading and investing.Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions.Medicine Matters Sharing successes, challenges and daily happenings in the Department of Medicine Nadia Hansel, MD, MPH, is the interim director of the Department of Medicine in the Johns Hopkins University School of Medicine and interim ph...Full details of the Editas Medicine presentations can be accessed in the Posters & Presentations section on the Company’s website.. About EDIT-103 EDIT-103 is a CRISPR/Cas9-based experimental ...Editas Medicine has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock on the same terms and conditions. All of the shares in the offering ...Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 12.83% so far this month. During the month of April, Editas Medicine Inc’s stock price has reached a high of $8.66 and a low of $6.33. Over the last year, Editas Medicine Inc has hit prices as high as $19.97 and as low as $6.33. Year to date, Editas ...Nov 24, 2023 · Stock analysis for Editas Medicine Inc (EDIT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. The experimental design and data interpretation in “Unexpected mutations after CRISPR–Cas9 editing in vivo” by Schaefer et al. are insufficient to support the conclusions drawn by the authorsThe Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the fourth quarter and full ...Editas Medicine Inc (EDIT) advanced chart and technical analysis tool allows you to add studies and indicators such as Moving Averages (SMA and EMA), MACD, ...Is Editas Medicine (NASDAQ:EDIT) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, pricing and company announcements to find out. Last updated Tuesday October 17th 8:22pm

Sep 29, 2023 · Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. The upgrade reflects optimism about Editas' progress in developing a gene-editing therapy ... US$262,437,000 (2019) Number of employees. 208 [2] (2020) Website. www .editasmedicine .com. Editas Medicine, Inc., (formerly Gengine, Inc. ), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. [3] [4] Editas headquarters is located in Cambridge, …Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.Editas Medicine (NASDAQ: EDIT), on the other hand, is down nearly 17% this year. Here are three reasons why Editas is a good buy now and one reason why it isn't. ... Analysts are high on the stock ...Instagram:https://instagram. 7 year treasury ratecontemporary art stocksandroxal buymortgage companies in va Conference Call The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the third quarter of 2023. To access the call, please dial 1-877-407-0989 (domestic) or 1-201-389-0921 (international) and ask for the Editas … stocks to shortapes stock Get Editas Medicine Inc (EDIT.OQ) real-time stock quotes, news, ... Editas Medicine, Inc. is a clinical-stage genome editing company.Shares of Editas Medicine ( EDIT 3.66%) are sliding today, down by 7.2% as of 11:26 a.m. ET. The decline came after the company announced a big shake-up with its research and development focus ... top gainers stock market Below is a summary of how these 5 analysts rated Editas Medicine over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the ...The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the fourth quarter and full ...